|Application ||IF, FC|
|Other Accession||3105, 181244, 654404, 77961, P30443, P30499|
|Isotype||Mouse / IgG1, kappa|
|Other Names||HLA class I histocompatibility antigen, B-7 alpha chain, MHC class I antigen B*7, HLA-B, HLAB|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||HLA-A (MHC I) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Involved in the presentation of foreign antigens to the immune system.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
HLA-A, with HLA-B and HLA-C, belongs to major histocompatibility complex (MHC) class I antigens and expresses constitutively on all nucleated cells. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation. This MAb is useful for HLA molecular typing of peripheral blood leukocytes as well as a large number of leukemic cell lines. It reacts with an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, -A28, -A29, -A30, -A31 and �Aw33). Its epitope maps between aa65-to-aa80 of the ?1 domain of the HLA-A. This MAb recognizes an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, A28, -A29, -A30, -A31 and -Aw33). Furthermore, by testing its reactivity with HLA-A2 natural variants and mutants, the importance of amino acid residues 79 and/or 80 of the α1 domain was demonstrated in the formation of an intralocus HLA-A determinant.
Domenech N et al. Hum Immunol 1991, 30(2):140-6 | Lozano F et al. Immunogenetics 1989, 30::50-3 | Lozano F et al. Tissue Antigens 1990, 35:193-5 | Young NT et al. Hum Immunol 1997, 52(1):1-11 | Krensky AM et al Transplant Proc 1996, 28(6):3026-8 | Hansen JA et al Hematol Oncol Clin North Am 1990, 4(3):507-515
If you have any additional inquiries please email technical services at email@example.com.